Literature DB >> 2105640

Renal changes in heterozygous Fabry's disease--a family study.

H C Chen1, J H Tsai, Y H Lai, J Y Guh.   

Abstract

Two sisters, one with a long history of proteinuria and the other of hematuria, came for examination. Physical examination and routine laboratory workups did not show any significant abnormalities. The renal ultrastructural changes in case 1 showed marked enlargement and foamy vacuolation of all the glomerular capillary visceral epithelial cells, which was not found in other glomerular cells. The renal changes in case 2 showed similar lesions but with fewer cells involved and also with less severity, but the involved cells showed marked lamellation within the vacuoles. The serum alpha-galactosidase activity was 4.9 and 3.0 nmol/h/mL serum, respectively (normal values, 12.1 +/- 1.6 nmol/h/mL serum, mean +/- SD, n = 11), thus confirming the heterozygous variety of Fabry's disease. Our findings in these two cases reveal that patients with heterozygous Fabry's disease may present with renal symptoms only, which may be either proteinuria or hematuria.

Entities:  

Mesh:

Year:  1990        PMID: 2105640     DOI: 10.1016/s0272-6386(12)80518-x

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  4 in total

1.  Proteinuria in a male adolescent with hearing loss: Answers.

Authors:  Gülşah Kaya Aksoy; Elif Çomak; Bahar Akkaya; Mustafa Koyun; Sema Akman
Journal:  Pediatr Nephrol       Date:  2017-11-02       Impact factor: 3.714

Review 2.  Fabry disease-what cardiologists can learn from the nephrologist: a narrative review.

Authors:  Christine E Kurschat
Journal:  Cardiovasc Diagn Ther       Date:  2021-04

Review 3.  Fabry disease in the era of enzyme replacement therapy: a renal perspective.

Authors:  Monique E Cho; Jeffrey B Kopp
Journal:  Pediatr Nephrol       Date:  2004-04-03       Impact factor: 3.714

Review 4.  Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?

Authors:  Stephen Waldek; Sandro Feriozzi
Journal:  BMC Nephrol       Date:  2014-05-06       Impact factor: 2.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.